Shenzhen Neptunus Bioengineer operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shenzhen Neptunus Bioengineer with three other
companies in this sector in China:
Harbin Pharmaceutical Group Company Limited
sales of 14.13 billion Chinese Renmimbi [US$2.05 billion]
of which 64%
was Medicine Trade),
Tasly Pharmaceutical Group Company Limited
(13.95 billion Chinese Renmimbi [US$2.02 billion]
of which 51%
was Medicine Commerce), and
Shanghai Fosun Pharmaceutical (Group) Company Limited
(14.51 billion Chinese Renmimbi [US$2.11 billion]
of which 70%
was Pharmaceutical Manufacturing and R&D).
During the year ended December of 2016, sales at
Shenzhen Neptunus Bioengineer were 13.61 billion Chinese Renmimbi (US$1.97 billion).
increase of 22.4%
versus 2015, when the company's sales were 11.12 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Shenzhen Neptunus Bioengineer
(and since 2011, sales have increased a total of 156%).
Sales of Pharmaceutical Appliance saw an increase
that was more than double the company's growth rate: sales were up
78.5% in 2016, from
645.61 million Chinese Renmimbi to 1.15 billion Chinese Renmimbi.
Not all segments of Shenzhen Neptunus Bioengineer experienced an increase in sales in 2016:
sales of Other Operating fell 32.4% to 23.94 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).
Shenzhen Neptunus Bioengineer also experienced decreases in sales in
Pharmaceutical Manufacturing (down 8.4% to 437.51 million Chinese Renmimbi)